

JAN 13 2004

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 66153/45004	
In Re Application Of: Chang et al.				
Serial No. 10/712,359	Filing Date November 13, 2003	Examiner Not yet assigned	Group Art Unit Not yet assigned	
Title: Dominant negative variants of methionine aminopeptidase 2 (METAP2) and clinical uses thereof				
Address to: Assistant Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450				
<b>37 CFR 1.97(b)</b>				
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.				
<b>37 CFR 1.97(c)</b>				
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:				
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);				
<b>OR</b>				
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).				

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 66153/45004	
In Re Application Chang et al.				
Serial No. 10/712,359	Filing Date November 13, 2003	Examiner Not yet assigned	Group Art Unit Not yet assigned	

### Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 20-0823 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

### Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. _____) on _____ _____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

  
 Signature

Daniel S. Kasten, Reg. #45363  
 Thompson Coburn LLP  
 One US Bank Plaza  
 St. Louis, Missouri 63101  
 314-552-6305  
 314-552-7305 FAX


CC:

### Certificate of Mailing by Express Mail

I certify that this document and fee is being deposited on January <u>12</u> , 2004 with the U.S. Postal Service as Express Mail "Post Office to Addressee" Mail Label No. <b>EL 991956773 US</b> mail under 37 C.F.R. 1.10 and addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  Signature of Person Mailing Correspondence
Daniel S. Kasten Typed or Printed Name of Person Mailing Certificate

Dated: January 12, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>		
 <p>Use as many sheets as necessary)</p>		Application Number	10/712,359	
		Filing Date	November 13, 2003	
		First Named Inventor	Chang	
		Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
1	of	3	Attorney Docket Number	66153-45004

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US- 6,261,794	07/17/01	Chang	
	AB	US- 5,888,796	03/30/99	Chang	
	AC	US- 5,885,820	03/23/99	Chang	
	AD	US- 6,110,744	08/29/2000	Fang et al.	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AE	BRADSHAW et al., Elsevier Science Ltd., <i>N-Terminal processing: the methionine aminopeptidase and N<sup>6</sup>-acetyl transferase families</i> , pages 263-267, 1998.	
	AF	GLOVER et al., J. of Biol. Chem., Vol. 272, No. 45, <i>Human N-Myristoyltransferase Amino-terminal Domain Involved in Targeting the Enzyme to the Ribosomal Subcellular Fraction</i> , pages 28680-28689, November 7, 1997.	
	AG	GRIFFITH et al., Chemistry & Biology, Vol. 4, No. 6, <i>Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin</i> , pages 461-471, 1997.	


Examiner Signature	Date Considered
--------------------	-----------------

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

 Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/712,359
				Filing Date	November 13, 2003
				First Named Inventor	Chang
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	3	Attorney Docket Number	66153-45004

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	AH	GRIFFITH et al., Proc. Natl. Acad. Sci. USA, Vol. 95, <i>Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2</i> , pages 15183-15188, December 1998.		
	AI	KLINKENBERG et al., Archives of Biochem. and Biophys., Vol. 347, No. 2, <i>A Dominant Negative Mutation in Saccharomyces cerevisiae Methionine Aminopeptidase-1 Affects Catalysis and Interferes with the Function of Methionine Aminopeptidase-2</i> , pages 193-200, November 15, 1997.		
	AJ	LI et al., Biochem. and Biophys. Research Comm., Vol. 227, Article 1482, <i>Evidence That the Human Homologue of a Rat Initiation Factor-2 Associated Protein (p<sup>67</sup>) is a Methionine Aminopeptidase</i> , pages 152-159, 1996.		
	AK	LOWTHER et al., Biochimica et Biophysica Acta, Vol. 1477, <i>Structure and function of the methionine aminopeptidases</i> , pages 157-167, 2000.		
	AL	TURK et al., Chemistry & Biology, Vol. 6, No. 11, <i>Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cell</i> , pages 1-11, 1999.		
	AM	GURA, TRISHA, Science Magazine, Vol. 276, <i>Systems for Identifying New Drugs are Often Faulty</i> , pages 1041-1042, November 7, 1997.		
	AN	FRESHNEY, R. IAN, <i>Culture of Animal Cells: A Manual of Basic Technique</i> , pages 3-4, New York, NY: Alan R. Liss, Inc., 1983.		
	AO	HARTWELL, et al. Science Magazine, vol. 278, <i>Integrating Genetic Approaches into the Discovery of Anticancer Drugs</i> , pages 1064-1068, November 7, 1997.		
	AP	KRUSE, et al., <i>Tissue Culture: Methods and Applications</i> , pages 764-766, New York: Academic Press, 1973.		
	AQ	DREXLER, HANS G., <i>Leukemia and Lymphoma</i> , Vol. 9, <i>Recent Results on the Biology of Hodgkin and Reed-Sternberg Cells</i> , pages 1-24, Harwood Academic Publishers GmbH, 1993.		
	AR	WRIGHT, GEORGE L., JR., <i>Monoclonal Antibodies and Cancer</i> , pages 181-207, New York, NY: Marcel Dekker, Inc., 1984.		
	AS	DERMER, GERALD B., <i>Bio/Technology</i> , Vol. 12, <i>Another Anniversary for the War on Cancer</i> , page 320, March 1994.		
	AT	CURTI, BRENDAN D., <i>Critical Reviews of Oncology/Hematology</i> , Vol. 14, <i>Physical barriers to drug delivery in tumors</i> , pages 29-39, Elsevier Scientific Publishers Ireland Ltd., 1993.		
	AU	VETRO, et al., <i>A Dominant Negative Mutant of Yeast Methionine Aminopeptidase Type 2 in Saccharomyces cerevisiae</i> , unpublished.		
	AV	BENDER, et al., <i>Mol. Cell Biol</i> , Vol. 11, No. 3, <i>Use of a screen for synthetic lethal and multicopy suppressor mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae</i> , pages 1295-1305, March 1991.		

Substitute for form 1449B/PTO 			<b>Complete if Known</b>		
			Application Number	10/712,359	
			Filing Date	November 13, 2003	
			First Named Inventor	Chang	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	3	of	3	Attorney Docket Number	66153-45004

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AW	PETERSON, et al., J. Cell Biol., Vol. 127, No. 5, <i>Interactions between the bud emergence proteins Bem1p and Bem2p and Rho-type GTPases in yeast</i> , pages 1395-1406, December 1994.	
	AX	KIM, et al., Molecular Biology of the Cell, Vol. 10, <i>High-Copy Suppressor Analysis Reveals a Physical Interaction between Sec34p and Sec 35p, a Protein Implicated in Vesicle Docking</i> , pages 3317-3329, The American Society for Cell Biology, October 1999.	
	AY	Simons, et al. Genome Research (www.genome.org), <i>Establishment of a Chemical Synthetic Lethality Screen in Cultured Human Cells</i> , pages 266-273, Cold Spring Harbor Laboratory Press, 2001.	
	AZ	MORRIS, et al. Journal of Biological Chemistry, <i>A New Potent HIV-1 Reverse Transcriptase Inhibitor: A Synthetic Peptide Derived from the Interface Subunit Domains</i> , pages 24941-24946, The American Society for Biochemistry and Molecular Biology, Inc., 1999.	
	BA	DIDIER, ELIZABETH, Antimicrobial Agents and Chemotherapy, Vol. 41, No. 7, <i>Effects of Albendazole, Fumagillin, and TNP-470 on Microsporidial Replication in Vitro</i> , pages 1541-1546, American Society for Microbiology, 1997.	
	BB	COYLE, et al. J. Infect Dis., Vol. 177, No. 2, <i>TNP-470 is an effective antimicrosporidial agent</i> , pages 515-518, February 1998.	
	BC	NICKLIN, et al., Hypertension, Vol. 38, No. 1, <i>Analysis of cell-specific promoters for viral gene therapy targeted at vascular endothelium</i> , pages 65-70, July 2001.	
	BD	HE, et al., Xenotransplantation, Vol. 8, No. 3, <i>The in vitro activity and specificity of human endothelial cell-specific promoters in porcine cells</i> , pages 202-212, August 2001.	
	BE	OPAVSKY, et al., J. Biol Chem, <i>Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal cells in vivo</i> , August 2001.	
	BF	TURK, et al., Bioorganic and Medicinal Chemistry, Vol. 6, <i>Synthetic Analogues of TNP-470 and Ovalicin Reveal a Common Molecular Basis for Inhibition of Angiogenesis and Immunosuppression</i> , pages 1163-1169, Elsevier Science Ltd., 1998.	
	BG	ZHANG, et al., PNAS, Vol. 97, No. 12, <i>Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 (WAF1/CIP1)</i> , pages 6427-6432, June 6, 2000.	
	BH	CARDENAS, et al., Clinical Microbiology Reviews, Vol. 12, No. 4, <i>Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System to Study Drug Action</i> , pages 583-611, American Society for Microbiology, 1999.	
	BI	DENTON, et al., American Society of Transplantation 18 <sup>th</sup> Annual Scientific Meeting, <i>TNP-470, An Anti-angiogenesis Agent, Is a Potent Inhibitor of Human CD4<sup>+</sup> T Cell Proliferation</i> , AST, 1997-2000.	
	BJ	LI, et al., Proc. Natl. Acad. Sci., Vol. 92, <i>Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases</i> , pages 12357-12361, December 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.